Oragenics Completes Approximately $16.5 Million Offering
Oragenics (NYSE American: OGEN) has successfully closed a public offering, raising $16.5 million through the issuance of 660,000 shares of Series H Convertible Preferred Stock and Warrants. Each unit, comprising one preferred share and one warrant, was priced at $25.00. The warrants could potentially generate an additional $16.5 million if fully exercised.
The preferred stock is convertible at $2.50 per common share, and the warrants expire in five years. The proceeds will primarily fund the development of ONP-002, an intranasal drug candidate for treating concussion, along with repaying a $3 million bridge note and supporting general corporate purposes.
Oragenics (NYSE American: OGEN) ha completato con successo un'offerta pubblica, raccogliendo 16,5 milioni di dollari tramite l'emissione di 660.000 azioni di Azioni Preferenziali Convertibili di Serie H e Warrants. Ogni unit脿, composta da un'azione preferenziale e un warrant, 猫 stata quotata a 25,00 dollari. I warrant potrebbero generare ulteriori 16,5 milioni di dollari se esercitati completamente.
Le azioni preferenziali sono convertibili a 2,50 dollari per azione ordinaria, e i warrant scadono entro cinque anni. I proventi saranno principalmente destinati allo sviluppo di ONP-002, un candidato farmaco intranasale per il trattamento della commozione cerebrale, oltre a rimborsare un prestito ponte di 3 milioni di dollari e a sostenere le attivit脿 generali aziendali.
Oragenics (NYSE American: OGEN) ha cerrado con 茅xito una oferta p煤blica, recaudando 16,5 millones de d贸lares mediante la emisi贸n de 660,000 acciones de Acciones Preferentes Convertibles Serie H y Warrants. Cada unidad, que incluye una acci贸n preferente y un warrant, se fij贸 en 25,00 d贸lares. Los warrants podr铆an generar un adicional de 16,5 millones de d贸lares si se ejercen en su totalidad.
Las acciones preferentes son convertibles a 2,50 d贸lares por acci贸n com煤n, y los warrants vencen en cinco a帽os. Los fondos se utilizar谩n principalmente para el desarrollo de ONP-002, un candidato a medicamento intranasal para tratar la conmoci贸n cerebral, junto con el pago de un pr茅stamo puente de 3 millones de d贸lares y para apoyar los prop贸sitos corporativos generales.
Oragenics (NYSE American: OGEN)電� 660,000欤检潣 鞁滊Μ歃� H 鞝勴櫂 鞖办劆欤� 氚� 鞗岆煱韸� 氚滍枆鞚� 韱淀暣 1,650毵� 雼煬鞚� 瓿惦毳� 靹标车鞝侅溂搿� 毵堦皭頄堨姷雼堧嫟. 臧� 鞙犽嫑鞚� 鞖办劆欤� 1欤检檧 鞗岆煱韸� 1欤茧 甑劚霅橂┌, 臧�瓴╈潃 25.00雼煬鞓�鞀惦媹雼�. 鞗岆煱韸戈皜 氇憪 頄夓偓霅橂┐ 於旉皜搿� 1,650毵� 雼煬毳� 臁半嫭頃� 靾� 鞛堨姷雼堧嫟.
鞖办劆欤茧姅 氤错喌欤� 1欤茧嫻 2.50雼煬鞐� 鞝勴櫂 臧�電ロ晿氅�, 鞗岆煱韸鸽姅 5雲� 頉� 毵岆霅╇媹雼�. 鞚措矆 鞛愱笀鞚� 欤茧 雵岇韮� 旃橂鞖� 牍勱皶 韴棳 鞎诫 頉勲炒鞚� ONP-002 臧滊皽鞐� 靷毄霅橂┌, 300毵� 雼煬鞚� 敫岆Μ歆� 雲疙姼 靸來櫂瓿� 鞚茧皹 旮办梾 氇╈爜 歆�鞗愳棎霃� 頇滌毄霅╇媹雼�.
Oragenics (NYSE American : OGEN) a cl么tur茅 avec succ猫s une offre publique, levant 16,5 millions de dollars gr芒ce 脿 l'茅mission de 660 000 actions privil茅gi茅es convertibles de s茅rie H et de bons de souscription (warrants). Chaque unit茅, compos茅e d'une action privil茅gi茅e et d'un warrant, a 茅t茅 fix茅e 脿 25,00 dollars. Les warrants pourraient g茅n茅rer un montant suppl茅mentaire de 16,5 millions de dollars s'ils sont enti猫rement exerc茅s.
Les actions privil茅gi茅es sont convertibles 脿 2,50 dollars par action ordinaire, et les warrants expirent dans cinq ans. Les fonds seront principalement utilis茅s pour le d茅veloppement de ONP-002, un candidat m茅dicament intranasal pour le traitement de la commotion c茅r茅brale, ainsi que pour le remboursement d'une avance de 3 millions de dollars et le soutien des besoins g茅n茅raux de l'entreprise.
Oragenics (NYSE American: OGEN) hat eine 枚ffentliche Platzierung erfolgreich abgeschlossen und dabei 16,5 Millionen US-Dollar durch die Ausgabe von 660.000 Aktien der Serie H Wandelvorzugsaktien und Warrants eingenommen. Jede Einheit, bestehend aus einer Vorzugsaktie und einem Warrant, wurde zu 25,00 US-Dollar bewertet. Die Warrants k枚nnten bei vollst盲ndiger Aus眉bung weitere 16,5 Millionen US-Dollar einbringen.
Die Vorzugsaktien sind zu 2,50 US-Dollar pro Stammaktie wandelbar, und die Warrants verfallen in f眉nf Jahren. Die Erl枚se werden haupts盲chlich zur Entwicklung von ONP-002, einem intranasalen Arzneimittelkandidaten zur Behandlung von Gehirnersch眉tterungen, sowie zur R眉ckzahlung einer 3 Millionen US-Dollar Br眉ckenfinanzierung und zur Unterst眉tzung allgemeiner Unternehmenszwecke verwendet.
- None.
- None.
Insights
Oragenics raises $16.5M for brain injury treatment development, potentially accessing another $16.5M through warrants, signaling important capital infusion.
Oragenics has successfully closed a
The financing architecture is particularly notable as it creates potential for an additional
The capital allocation strategy prioritizes advancement of ONP-002, their intranasal drug candidate targeting concussion treatment. The funds will also support broader R&D initiatives, repay a
The successful completion of this offering during challenging biotech financing conditions suggests investor confidence in Oragenics' neurological disorder treatment approach. The market's reception to this offering may indicate growing interest in novel drug delivery systems for brain injuries, a significant unmet medical need with substantial market potential.
Proceeds to drive development of ONP-002, the Company鈥檚 lead intranasal drug candidate for mild traumatic brain injury
SARASOTA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering intranasal therapeutics for neurological disorders, today announced the successful closing of its previously announced public offering of Series H Convertible Preferred Stock and Warrants. The Company secured total gross proceeds of approximately
As part of the transaction, Oragenics issued 660,000 shares of its Series H Convertible Preferred Stock, no par value, together with Warrants to purchase up to 660,000 additional shares of Series H Convertible Preferred Stock. Each unit, consisting of one share of Preferred Stock and one Warrant, was sold at a combined public offering price of
The Series H Convertible Preferred Stock is convertible into shares of Oragenics鈥� common stock, par value
The Company intends to use the net proceeds from the offering to advance the clinical development of ONP-002, its intranasal drug candidate for the treatment of concussion (mild traumatic brain injury), support other research and development activities, repay a
鈥淲e are pleased to have completed this transaction and are encouraged by the strong investor support, which we believe reflects growing confidence in our science and strategy,鈥� said Janet Huffman, Chief Executive Officer of Oragenics. 鈥淲e anticipate the net proceeds of this offering will allow us to accelerate the advancement of ONP-002 and position Oragenics as a leader in the treatment of concussion through novel intranasal delivery.鈥�
Dawson James Securities, Inc. acted as the sole placement agent for the offering.
The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-288225), which was declared effective by the U.S. Securities and Exchange Commission (the 鈥淪EC鈥�) on June 30, 2025. A final prospectus relating to the offering has been filed with the SEC and is available on the SEC鈥檚 website at www.sec.gov. Copies of the final prospectus may also be obtained from Dawson James Securities, Inc., 101 North Federal Highway, Suite 600, Boca Raton, FL 33432, by telephone at (561) 391-5555, or by email at .
Shumaker, Loop & Kendrick, LLP, Tampa, FL, represented the Company in connection with the offering, and ArentFox Schiff LLP, Washington, DC, represented the placement agent.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About Oragenics
Oragenics is a development-stage biotechnology company focused on the nasal delivery of pharmaceutical medications for neurological disorders and infectious diseases. Its lead therapeutic candidate, ONP-002, is an intranasal drug in development for the treatment of mild traumatic brain injury (concussion). The Company also holds proprietary rights to a dry powder formulation and a novel intranasal delivery device. For more information, please visit www.oragenics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the completion and proceeds of the offering, the use of proceeds, and the clinical advancement of ONP-002. These statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described herein. Additional information regarding these risks can be found in Oragenics鈥� filings with the SEC. Oragenics undertakes no obligation to publicly update or revise any forward-looking statements unless required by law.
Oragenics, Inc.
Janet Huffman, Chief Executive Officer
813-286-7900
听
Investor Contact
Rich Cockrell
404.736.3838
听
